WO2009014863A3 - Asc and pyrin-asc pyroptosomes and uses thereof - Google Patents

Asc and pyrin-asc pyroptosomes and uses thereof Download PDF

Info

Publication number
WO2009014863A3
WO2009014863A3 PCT/US2008/068747 US2008068747W WO2009014863A3 WO 2009014863 A3 WO2009014863 A3 WO 2009014863A3 US 2008068747 W US2008068747 W US 2008068747W WO 2009014863 A3 WO2009014863 A3 WO 2009014863A3
Authority
WO
WIPO (PCT)
Prior art keywords
asc
pyroptosomes
pyrin
inflammation
detecting
Prior art date
Application number
PCT/US2008/068747
Other languages
French (fr)
Other versions
WO2009014863A2 (en
WO2009014863A9 (en
Inventor
Emad S Alnemri
Original Assignee
Univ Jefferson
Emad S Alnemri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson, Emad S Alnemri filed Critical Univ Jefferson
Publication of WO2009014863A2 publication Critical patent/WO2009014863A2/en
Publication of WO2009014863A9 publication Critical patent/WO2009014863A9/en
Publication of WO2009014863A3 publication Critical patent/WO2009014863A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to the field of immune responses and to inflammation. Embodiments of the invention relate to methods of: (1) isolating and detecting inflammasomes associated with pyroptosis-ASC pyroptosomes; (2) diagnosing inflammation; (3) detecting pathogen; (4) screening for anti-inflammatory agents; and (5) treatment of auto-inflammatary diseases and disorder.
PCT/US2008/068747 2007-06-29 2008-06-30 Asc and pyrin-asc pyroptosomes and uses thereof WO2009014863A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93772207P 2007-06-29 2007-06-29
US60/937,722 2007-06-29
US95132607P 2007-07-23 2007-07-23
US60/951,326 2007-07-23

Publications (3)

Publication Number Publication Date
WO2009014863A2 WO2009014863A2 (en) 2009-01-29
WO2009014863A9 WO2009014863A9 (en) 2009-03-26
WO2009014863A3 true WO2009014863A3 (en) 2009-05-07

Family

ID=40139238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068747 WO2009014863A2 (en) 2007-06-29 2008-06-30 Asc and pyrin-asc pyroptosomes and uses thereof

Country Status (1)

Country Link
WO (1) WO2009014863A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160807A1 (en) 2012-04-24 2013-10-31 Sahillioglu Ali Can A method for antigen delivery
SG10202106385XA (en) * 2016-12-29 2021-07-29 Univ Miami Method for modulating inflammasome activity and inflammation in the lung
CN114641315A (en) * 2019-11-14 2022-06-17 博阿济吉大学 ASC spots in cancer immunotherapy
CN112011499B (en) * 2020-09-10 2022-06-03 徐州医科大学 Method for preparing extracellular vesicles and application thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 98, no. 11 Part 1, 2001, 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 229a *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, SHIOHARA MASAAKI ET AL: "ASC, which is composed of a pyrin-N-terminal homology domain and a caspase-recruitment domain, is up-regulated by inflammation and apoptosis in human neutrophils", XP002509226, Database accession no. PREV200200163535 *
FERNANDES-ALNEMRI T ET AL: "The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation", CELL DEATH AND DIFFERENTIATION, vol. 14, no. 9, 29 June 2007 (2007-06-29), pages 1590 - 1604, XP002509224 *
MASUMOTO J ET AL: "ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 48, 1999, pages 33835 - 33838, XP002191744 *
SALEH M ET AL: "Caspase-1 inflammasomes: choosing between death and taxis", CELL DEATH AND DIFFERENTIATION, vol. 14, no. 9, September 2007 (2007-09-01), pages 1559 - 1560, XP002509220 *
SRINIVASULA S M ET AL: "The PYRIN-CARD protein ASC is an activating adaptor for caspase-1", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 24, 2002, pages 21119 - 21122, XP002213421 *
STEHLIK C ET AL: "Apoptosis-Associated Speck-Like Protein Containing a Caspase Recruitment Domain Is a Regulator of Procaspase-1 Activation", JOURNAL OF IMMUNOLOGY, vol. 171, no. 11, 2003, pages 6154 - 6163, XP002509223 *
STEHLIK CHRISTIAN ET AL: "The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappaB and pro-caspase-1 regulation.", BIOCHEMICAL JOURNAL, vol. 373, no. 1, 2003, pages 101 - 113, XP002509222 *
YU J -W ET AL: "Pyrin Activates the ASC Pyroptosome in Response to Engagement by Autoinflammatory PSTPIP1 Mutants", MOLECULAR CELL, vol. 28, no. 2, 26 October 2007 (2007-10-26), pages 214 - 227, XP002509225 *
YU S P: "Regulation and critical role of potassium homeostasis in apoptosis.", PROGRESS IN NEUROBIOLOGY, vol. 70, no. 4, 2003, pages 363 - 386, XP002509221 *

Also Published As

Publication number Publication date
WO2009014863A2 (en) 2009-01-29
WO2009014863A9 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
HUS2100015I1 (en) Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
CY1121327T1 (en) MODIFIED ANTIBODIES ANTI-IL-23P19
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EP4269563A3 (en) Anti-gd2 antibodies
EP1888765A4 (en) Methods and compositions for the diagnosis of venous thromboembolic disease
WO2006029183A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2009010765A (en) Anti-ige antibodies.
WO2007109056A3 (en) Use of gelsolin to diagnose and treat inflammatory diseases
WO2008079363A3 (en) Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
WO2007111661A3 (en) Human antibodies specific for gastrin materials and methods
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2006116609A3 (en) Methods for treating lower motor neuron diseases and compositions for the same
GB2459609A (en) Methods for allergen detection
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2006109301A3 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
WO2009014863A3 (en) Asc and pyrin-asc pyroptosomes and uses thereof
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2006113347A3 (en) Diagnostic and therapeutic potential of immune globulin intravenous (igiv) products
WO2008022263A3 (en) Methods for lymph system imaging
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
WO2009146463A8 (en) Variant hhip1 protein and methods and uses thereof
WO2010077323A3 (en) Compositions and methods for diagnosing and treating inflammatory bowel disease and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08826513

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08826513

Country of ref document: EP

Kind code of ref document: A2